🎉 M&A multiples are live!
Check it out!

Dynavax Valuation Multiples

Discover revenue and EBITDA valuation multiples for Dynavax and similar public comparables like Vivoryon Therapeutics, Julphar, and Galapagos.

Dynavax Overview

About Dynavax

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.


Founded

1996

HQ

United States of America
Employees

405

Website

dynavax.com

Financials

LTM Revenue $287M

LTM EBITDA $45.4M

EV

$1.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Dynavax Financials

Dynavax has a last 12-month revenue of $287M and a last 12-month EBITDA of $45.4M.

In the most recent fiscal year, Dynavax achieved revenue of $277M and an EBITDA of $45.7M.

Dynavax expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Dynavax valuation multiples based on analyst estimates

Dynavax P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $232M $277M XXX XXX XXX
Gross Profit $461M $182M XXX XXX XXX
Gross Margin 198% 66% XXX XXX XXX
EBITDA $9.7M $45.7M XXX XXX XXX
EBITDA Margin 4% 16% XXX XXX XXX
Net Profit $293M -$6.4M XXX XXX XXX
Net Margin 126% -2% XXX XXX XXX
Net Debt $19.6M $72.4M XXX XXX XXX

Financial data powered by Morningstar, Inc.

Dynavax Stock Performance

As of March 14, 2025, Dynavax's stock price is $14.

Dynavax has current market cap of $1.7B, and EV of $1.3B.

See Dynavax trading valuation data

Dynavax Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$1.3B $1.7B XXX XXX XXX XXX $0.23

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Dynavax Valuation Multiples

As of March 14, 2025, Dynavax has market cap of $1.7B and EV of $1.3B.

Dynavax's trades at 4.4x LTM EV/Revenue multiple, and 27.8x LTM EBITDA.

Analysts estimate Dynavax's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Dynavax and 10K+ public comps

Dynavax Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $1.3B XXX XXX XXX
EV/Revenue 4.5x XXX XXX XXX
EV/EBITDA 27.6x XXX XXX XXX
P/E 63.0x XXX XXX XXX
P/E/Growth 0.8x XXX XXX XXX
EV/FCF 21.0x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Dynavax Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Dynavax Valuation Multiples

Dynavax's NTM/LTM revenue growth is 18%

Dynavax's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.6M for the same period.

Over next 12 months, Dynavax's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Dynavax's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Dynavax and other 10K+ public comps

Dynavax Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 19% XXX XXX XXX XXX
EBITDA Margin 16% XXX XXX XXX XXX
EBITDA Growth 373% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 34% XXX XXX XXX XXX
Revenue per Employee $0.7M XXX XXX XXX XXX
Opex per Employee $0.6M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 61% XXX XXX XXX XXX
R&D Expenses to Revenue 22% XXX XXX XXX XXX
Opex to Revenue 84% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Dynavax Public Comps

See public comps and valuation multiples for Biopharmaceuticals and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
Armata Pharmaceuticals XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Dynavax M&A and Investment Activity

Dynavax acquired  XXX companies to date.

Last acquisition by Dynavax was  XXXXXXXX, XXXXX XXXXX XXXXXX . Dynavax acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Dynavax

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Dynavax

When was Dynavax founded? Dynavax was founded in 1996.
Where is Dynavax headquartered? Dynavax is headquartered in United States of America.
How many employees does Dynavax have? As of today, Dynavax has 405 employees.
Who is the CEO of Dynavax? Dynavax's CEO is Mr. Ryan Spencer.
Is Dynavax publicy listed? Yes, Dynavax is a public company listed on NAS.
What is the stock symbol of Dynavax? Dynavax trades under DVAX ticker.
When did Dynavax go public? Dynavax went public in 2004.
Who are competitors of Dynavax? Similar companies to Dynavax include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics.
What is the current market cap of Dynavax? Dynavax's current market cap is $1.7B
What is the current revenue of Dynavax? Dynavax's last 12-month revenue is $287M.
What is the current EBITDA of Dynavax? Dynavax's last 12-month EBITDA is $45.4M.
What is the current EV/Revenue multiple of Dynavax? Current revenue multiple of Dynavax is 4.4x.
What is the current EV/EBITDA multiple of Dynavax? Current EBITDA multiple of Dynavax is 27.8x.
What is the current revenue growth of Dynavax? Dynavax revenue growth between 2023 and 2024 was 19%.
Is Dynavax profitable? Yes, Dynavax is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.